The endocannabinoid signalling system was discovered because receptors in this system
are the targets of compounds present in psychotropic preparations of Cannabis sativa. The …

Background. Cannabis use is common in North America, especially among young people,
and is associated with a risk of various acute and chronic adverse health outcomes …

Background Public and medical interest in cannabidiol (CBD) has been rising, and CBD is
now available from various sources. Research into the effects of low-dose CBD on outcomes …

Background Approximately 188 million people use cannabis yearly worldwide, and it has
recently been legalised in 11 US states, Canada, and Uruguay for recreational use. The …

To present a summary of current scientific evidence about the cannabinoid, cannabidiol
(CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders …

Cannabis (also known as marijuana) is the most frequently used illicit psychoactive
substance in the world. Though it was long considered to be a “soft” drug, studies have …

Based upon evidence that the therapeutic properties of C annabis preparations are not
solely dependent upon the presence of Δ9‐tetrahydrocannabinol (THC), pharmacological …

Abstract Cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) are the most represented
phytocannabinoids in Cannabis sativa plants. However, CBD may present with a different …

The recent liberalisation of cannabis regulation has increased public and scientific debate
about its potential benefits and risks. A key focus has been the extent to which cannabidiol …

Considering data from in vitro and in vivo studies, cannabidiol (CBD) seems to be a
promising candidate for the treatment of both somatic and psychiatric disorders. The aim of …